Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation

ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells

(2016) Reshma Thamkachy et al.   Molecular Cancer

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line

(2015) Dong Yan et al.   OncoTargets and Therapy

Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5

(2015) Xu Di et al.   Oncotarget

Enhancement of tumor-TRAIL susceptibility by modulation of autophagy

(2014) Wen Hou et al.   Autophagy

TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages

(2013) Bao-Zhu Yuan et al.   BMC CANCER

Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors

(2013) Mohammad Shoeb et al.   FREE RADICAL BIOLOGY AND MEDICINE

Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer

(2013) Wieslawa H. Dragowska et al.   PLoS One

Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors

(2012) Hairong Cheng et al.   CELL CYCLE

Control of FLIPL expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells

(2012) R Yerbes et al.   CELL DEATH AND DIFFERENTIATION

EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis

(2012) Fei Xu et al.   Chinese Journal of Cancer

EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells

(2011) Weidong Han et al.   PLoS One

Off-Target Lapatinib Activity Sensitizes Colon Cancer Cells Through TRAIL Death Receptor Up-Regulation

(2011) N. G. Dolloff et al.   Science Translational Medicine

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells

(2008) Jie Han et al.   JOURNAL OF BIOLOGICAL CHEMISTRY